Neuroendocrine tumours trials in Portugal

4 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

• Phase 2Taking people
  Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  Where

  Lisbon, Porto

  Age

  12 years and over

  People

  355 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT04924075 · EU 2023-504853-11-00
• Phase 3Taking people
  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Where

  Lisbon, Porto

  Age

  18 years and over

  People

  390 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07544654 · EU 2025-523869-22-00
• Phase 3Taking people
  Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)

  Where

  Lisbon, Senhora Da Hora

  Age

  18 years and over

  People

  156 worldwide

  Run by

  Amgen Inc.

  See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
• Phase 2Taking people
  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  Where

  Lisbon, Matosinhos, Porto

  Age

  18 years and over

  People

  204 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT05882058 · EU 2023-504247-13-00